Social Intelligence in Pharmaceuticals

In our latest white paper series, we explore the topic of digital readiness while breaking down the online commentary related to FDA’s approval of ADUHELM (aducanumab).

The author(s)

  • Steve Reeves Vice President Social Intelligence Anlaytics
  • Pete Duncan Data Scientist & Co-Lead of Ipsos Healthcare Social Intelligence CoE
  • Michele Drennen SVP, Ipsos Healthcare
  • Jackson Lambert Ipsos Healthcare Intern Notre Dame School of Engineering
Get in touch

In the past several years, a sizable increase has been notable in the use of social data and online channels for research by the pharma­ceutical, biotechnology and MedTech industries.

To illustrate just how social data can quickly surface perspectives from a variety of healthcare stakeholders in near-real time, Ipsos sought to break down the online commentary regarding FDA’s recent ADUHELM approval for the treatment of early-onset Alzheimer’s. In this three-part white paper series, we share our detailed research examining the cumula­tive effect of online views and voices that have arisen as a result of this market event:

  1. A Comprehensive Examination of the Alzheimer’s Online Eco-system: This paper highlights the overall impact of the ADUHELM news on the wider AD online ecosystem.
  2. Voice of Patient and Caregiver Perspectives: This paper shares intelligence from the patient and caregiver point of view.
  3. Physician and HCP Perspectives: This paper offers detailed insights into the physician and HCP point of view.

If you are interested in receiving customized social intelligence analysis or gain a better understanding of the patient and medical community perspectives, please contact us.

The author(s)

  • Steve Reeves Vice President Social Intelligence Anlaytics
  • Pete Duncan Data Scientist & Co-Lead of Ipsos Healthcare Social Intelligence CoE
  • Michele Drennen SVP, Ipsos Healthcare
  • Jackson Lambert Ipsos Healthcare Intern Notre Dame School of Engineering

Consumer & Shopper